Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region (ASC4Young)

9 november 2026 uppdaterad av: Novartis Pharmaceuticals

ASC4Young: Real-World Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region

The aim of this study is to evaluate the real-world effectiveness and safety of asciminib among young adults with chronic myeloid leukemia (CML) across the Gulf region. The data source for this study will consist of routinely collected clinical information documented within the electronic health records (EHR) of participating centers.

Studieöversikt

Status

Har inte rekryterat ännu

Studietyp

Observationell

Inskrivning (Beräknad)

80

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Novartis Pharmaceuticals

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 99 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

CML patients who initiate asciminib between 01 May 2023 and 31 May 2026 in participating centers across the Gulf region.

Beskrivning

Inclusion Criteria

  • Confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP)
  • Adult patients aged ≥ 18 years at the index date (or adult as defined by applicable national regulations)
  • Documented exposure to asciminib during the identification period (May 2023 to May 2026)
  • Provision of signed informed consent for secondary use of data, or an ethics committee-approved waiver of consent, where applicable (including for deceased patients or where data were previously collected within the EHR system)

Exclusion Criteria

  • Patients who do not meet the eligibility criteria specified above
  • Patients with insufficient medical record documentation to determine asciminib exposure or key study outcomes

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: RETROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Young Adults Cohort

CML patients aged ≤ 40 years at the first documented asciminib administration.

Older Adults Cohort

CML patients aged > 40 years at the first documented asciminib administration.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Major Molecular Response (MMR) Rate in Young Adults
Tidsram: Approximately 12 Months

MMR is defined as a BCR::ABL1 level on the International Scale (BCR::ABL1 IS) ≤ 0.1%.

Approximately 12 Months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of Adverse Events (AEs)
Tidsram: Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Number of Treatment Interruptions Due to AEs
Tidsram: Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Duration of Treatment Interruptions Due to AEs
Tidsram: Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Time to Treatment Discontinuation due to Adverse Events (TTDAE)
Tidsram: Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 10% After 3 Months of Treatment
Tidsram: 3 months
3 months
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 1% After 6 Months of Treatment
Tidsram: 6 months
6 months
Number of Patients With Prior Tyrosine Kinase Inhibitor (TKI) Treatment
Tidsram: Up to 12 months prior to Baseline
Up to 12 months prior to Baseline
Duration of CML at Time of Asciminib Treatment Initiation
Tidsram: Baseline
Baseline
Asciminib Starting Dose
Tidsram: Baseline
Baseline
Number of Treatment Interruptions
Tidsram: Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Duration of Treatment Interruptions
Tidsram: Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Number of Patients by Reasons for Treatment Interruptions and Subsequent Treatment Switching
Tidsram: Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Number of Patients by Reason for Treatment Switch
Tidsram: Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Number of Patients by Type and Severity of AEs
Tidsram: Approximately 3, 6, and 12 months

Number of patients by type and severity of AEs including serious AEs and grade ≥ 3 AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

Approximately 3, 6, and 12 months
Incidence of AEs Leading to Dose Modifications
Tidsram: Approximately 3, 6, and 12 months

Dose modifications include treatment interruptions and dose reductions.

Approximately 3, 6, and 12 months
MMR in Patients Aged > 40 years
Tidsram: Approximately 12 months

MMR is defined as BCR::ABL1 IS ≤ 0.1%.

Approximately 12 months
Rate of Deep Molecular Response
Tidsram: Approximately 12 months

Deep molecular response includes:

  • Molecular response (MR) 4.0 (BCR::ABL1 IS ≤ 0.01%), and
  • MR4.5 (BCR::ABL1 IS ≤ 0.0032%), where available.
Approximately 12 months
Number of Patients With Dose Modifications
Tidsram: Approximately 3, 6, and 12 months

Number of patients with dose modifications including up titration or dose reduction.

Approximately 3, 6, and 12 months
Number of Patients by Clinicopathological Characteristics
Tidsram: Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline

Clinicopathological characteristics include:

  • Demographics (gender, ethnicity, nationality, smoking status, and insurance status)
  • Clinical presentation (signs and symptoms of disease)
  • Laboratory parameters (lipid panel, complete blood count, clinical chemistry, kidney, liver and pancreas function tests)
  • Molecular findings (BCR::ABL1 transcript types, additional cytogenetic abnormalities, and other reported mutations)
Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 december 2026

Primärt slutförande (Beräknad)

1 september 2027

Avslutad studie (Beräknad)

1 september 2027

Studieregistreringsdatum

Först inskickad

26 juni 2026

Först inskickad som uppfyllde QC-kriterierna

26 juni 2026

Första postat (Faktisk)

2 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

10 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 november 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera